Dr. Lewis Mervin

Lewis has spent over a decade developing and applying machine learning methods in drug discovery. Before joining Apheris, he founded a molecular property prediction platform and spent six years at AstraZeneca, where he worked on predictive modelling across chemistry, ADMET, and pharmacology. Lewis holds a PhD in Chemistry from the University of Cambridge and has contributed to major collaborative initiatives in the field, including the MELLODDY federated learning consortium and the JUMP–Cell Painting program, helping to shape how industry approaches shared model development. Publications: Google Scholar